Adrenocortical Carcinoma Pipeline Insight 2025: Targeted Therapies and Immuno-Oncology Efforts Gain Traction | DelveInsight

DelveInsight's "Adrenocortical Carcinoma - Pipeline Insight, 2025" provides a comprehensive look into the evolving therapeutic pipeline for Adrenocortical Carcinoma (ACC)-a rare, aggressive malignancy originating in the adrenal cortex. ACC accounts for a small fraction of adrenal tumors but often presents with poor prognosis, high recurrence rates, and limited treatment options, especially in advanced or metastatic stages.

ACC is frequently associated with hormonal excess (such as cortisol or androgen overproduction), adding clinical complexity to management. Current frontline treatment strategies involve surgical resection, mitotane therapy, and platinum-based chemotherapy. However, outcomes remain suboptimal, spurring innovation in targeted and immune-based therapies.

Recent years have seen a resurgence of research interest in ACC, fueled by a better understanding of its molecular pathogenesis, including mutations in TP53, CTNNB1, IGF2, and MEN1. These insights are driving the development of targeted therapies aimed at interrupting oncogenic signaling pathways such as IGF-1R/PI3K/AKT/mTOR and Wnt/β-catenin.

Parallelly, immunotherapy is emerging as a promising avenue, with checkpoint inhibitors under investigation in multiple early-phase trials. Despite the immunosuppressive tumor microenvironment of ACC, combination approaches integrating immunotherapy with mitotane or radiation are being explored to overcome resistance and boost efficacy.

The pipeline also includes novel small molecules, kinase inhibitors, and synthetic lethality approaches, along with efforts to repurpose drugs across rare endocrine malignancies. Biomarker-driven trial designs and genomic profiling are becoming central to identifying suitable patient subsets and improving clinical outcomes.

With orphan drug designations and global research collaborations, ACC is gradually gaining visibility in the rare oncology space. Although still in early stages, the 2025 pipeline reflects cautious optimism, with a growing emphasis on precision oncology and multi-modal regimens to tackle this challenging and under-addressed malignancy.

Interested in learning more about the current treatment landscape and the key drivers shaping the Adrenocortical Carcinoma pipeline? Click here: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Adrenocortical Carcinoma Pipeline Report
• DelveInsight's Adrenocortical Carcinoma pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for Adrenocortical Carcinoma treatment.
• The leading Adrenocortical Carcinoma companies include Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech, and others are evaluating their lead assets to improve the Adrenocortical Carcinoma treatment landscape.
• Key Adrenocortical Carcinoma pipeline therapies in various stages of development include Relacorilant, Ipilimumab, EO 2401, Cabozantinib, Atezolizumab, and others.
• In May 2025, the FDA expanded the indication for Merck's WELIREG (belzutifan) to include treatment of pheochromocytoma and paraganglioma (rare adrenal gland tumors) in patients aged 12 and up with metastatic or inoperable disease. Although not direct ACC therapy, this oral treatment strengthens Merck's focus on adrenal cancers and may pave the way for exploring similar mechanisms in ACC‐linked tumors.

Request a sample and discover the recent breakthroughs happening in the Adrenocortical Carcinoma pipeline landscape at https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Adrenocortical Carcinoma Overview
Adrenocortical carcinoma (ACC) is a rare and aggressive cancer originating in the outer layer of the adrenal glands, which are responsible for producing essential hormones like cortisol, aldosterone, and androgens. ACC can be either functional-producing excess hormones-or non-functional. Functional tumors often cause symptoms related to hormone imbalance, such as weight gain, high blood pressure, and abnormal hair growth, while non-functional tumors may remain asymptomatic until they grow large enough to press on nearby organs.

Diagnosis typically involves imaging studies, hormonal evaluations, and biopsy. Due to its rarity and often late-stage diagnosis, ACC has a poor prognosis, particularly in advanced stages. Treatment usually involves surgical resection, which is the primary option for localized tumors, often followed by mitotane or other adjuvant therapies. Research into targeted therapies and immunotherapy is ongoing, aiming to improve outcomes in patients with metastatic or recurrent disease.

Find out more about Adrenocortical Carcinoma medication at https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Adrenocortical Carcinoma Treatment Analysis: Drug Profile
Relacorilant: Corcept Therapeutics
Relacorilant is a selective, non-steroidal modulator of the glucocorticoid receptor, which is activated in response to elevated cortisol levels. Unlike other treatments, it does not interact with other hormone receptors in the body. Corcept is evaluating relacorilant for its potential to treat various serious conditions, including Cushing's syndrome as well as advanced adrenal, ovarian, and pancreatic cancers.

Ipilimumab: Bristol-Myers Squibb
Ipilimumab (brand name Yervoy) is a fully human monoclonal antibody targeting CTLA-4, a protein that downregulates T-cell immune responses. By blocking CTLA-4 from binding to its ligands (CD80/CD86), ipilimumab enhances T-cell activation and proliferation, including tumor-infiltrating T cells. This immune activation also reduces T-regulatory cell function, helping strengthen the overall anti-tumor response. Ipilimumab is currently in Phase II trials for the treatment of adrenocortical carcinoma.

Learn more about the novel and emerging Adrenocortical Carcinoma pipeline therapies at https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Adrenocortical Carcinoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Adrenocortical Carcinoma Pipeline Report
• Coverage: Global
• Key Adrenocortical Carcinoma Companies: Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech, and others.
• Key Adrenocortical Carcinoma Pipeline Therapies: Relacorilant, Ipilimumab, EO 2401, Cabozantinib, Atezolizumab, and others.

To dive deep into rich insights for drugs used for Adrenocortical Carcinoma treatment, visit: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Adrenocortical Carcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Adrenocortical Carcinoma Pipeline Therapeutics
6. Adrenocortical Carcinoma Pipeline: Late-Stage Products (Phase III)
7. Adrenocortical Carcinoma Pipeline: Mid-Stage Products (Phase II)
8. Adrenocortical Carcinoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.